| Budget Amount *help |
¥1,600,000 (Direct Cost: ¥1,600,000)
Fiscal Year 1994: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1993: ¥800,000 (Direct Cost: ¥800,000)
|
|---|
| Research Abstract |
In this study, the author first, developed in vivo method of adriamycine Binding Assay (ABA) which has been proved to be able to quickly detect sensitivity not only to adriamycine (ADR) also to multi-anticancer drugs in cultured cell lines and secondly, investigated relationship between adriamycin binding ratio and clinical or histological effect of chemotherapy in human bone nad soft tissue tumors. Living tumor cells were isolated from fresh biopsied materials with collagenase and incubated with 10ug/ml ADR for 30 min. Only living cells were then stained with fluorescein diacetate (FDA). Under observation with fluorescence microscope, the living cells with ADR fluorescence in nucleus were evaluated to be sensitive to ADR,but ones without ADR were resistant. %AB showed frequency of sensitive cells in all of the living cells measured. Fourty-four patients were analyzed. In most of the patients with recurrence or metastasis after chemotherapy to primary tumor, or with metastatic disease at diagnosis of primary tumor, %AB was less than 80%. This strongly suggests that tumors with low %AB are multi-drug resistant. Of 11 patients with primary tumor lesion without metastasis and any kind of previous chemotherapy, 4 with %AB more than 80% were histologically sensitive to chemotherapy after preoperative chemotherapy, whereas remaining 7 with %AB less than 80% except one were resistant. It also shows that %AB is correlated with chemotherapy effect well. The author, therefore concluded that ABA is one of the excellent chemosensitivity tests and avalable to clinical usage, because it is able to predict sensitivity to chemotherapy more quickly and accurately than other chemosensitivity tests previously reported.
|
